Home LiteratureArticle Details
PMID: 12540051 Published · ppublish English Journal Article Review

Discovery of compounds that will prevent tau pathology.

Journal of molecular neuroscience : MN ·Vol. 19 ·No. 3 ·2002-12-00 ·Pages 261-6

Kosik KS, Ahn J, Stein R, Yeh LA

Abstract

Tau is certainly a reasonable target for the development of compounds to prevent neurofibrillary pathology, particularly in the fronto-temporal dementias. Although the mechanism of the filamentous accumulations remains unclear, sufficient knowledge is in place to move forward with high throughput screens. In fact, the development of compounds from such screens will ultimately be the only way to validate the target. The dichotomy for such screens is that in vitro screens are easier to design, but require more assumptions as to the mechanism, in contrast to cell-based screens that are more difficult to design, but make fewer assumptions about mechanism. We have designed a moderate throughput for tau binding that relies on fluorescence detection in living cells and an in vitro cdk5/p25 tau phosphorylation high throughput screen.

MeSH Terms
Animals Cyclin-Dependent Kinase 5 Cyclin-Dependent Kinases/metabolism Drug Design Drug Evaluation, Preclinical/methods Humans Mutation Nerve Tissue Proteins/metabolism Phosphorylation/drug effects Protein Binding/drug effects,physiology Tauopathies/prevention & control tau Proteins/genetics,metabolism
Chemicals
Nerve Tissue Proteins neuronal Cdk5 activator (p25-p35) tau Proteins Cyclin-Dependent Kinase 5 CDK5 protein, human Cyclin-Dependent Kinases
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Kosik Kenneth S
Harvard Medical School, Brigham and Women's Hospital, 77 Ave. Louis Pasteur, Boston, MA 02115, USA. [email protected]
Ahn Jae
Stein Ross
Yeh Li-An
References (55)
55 references, click to expand
  1. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.
    Neurosci Lett. 1992 Nov 23;147(1):58-62 PMID: 1336152
  2. Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells.
    Neurosci Lett. 1995 Sep 8;197(2):149-53 PMID: 8552282
  3. Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites.
    Neurosci Lett. 1995 Dec 29;202(1-2):81-4 PMID: 8787836
  4. Tau protein pathology in neurodegenerative diseases.
    Trends Neurosci. 1998 Oct;21(10):428-33 PMID: 9786340
  5. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.
    Neuron. 1989 Oct;3(4):519-26 PMID: 2484340
  6. Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau.
    J Neurosci. 2002 Feb 1;22(3):698-707 PMID: 11826099
  7. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly.
    Mol Biol Cell. 1997 Feb;8(2):353-65 PMID: 9190213
  8. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau.
    FEBS Lett. 1992 Dec 21;314(3):315-21 PMID: 1334849
  9. Structure and regulation of the CDK5-p25(nck5a) complex.
    Mol Cell. 2001 Sep;8(3):657-69 PMID: 11583627
  10. The microtubule binding domain of tau protein.
    Neuron. 1989 Jun;2(6):1615-24 PMID: 2516729
  11. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.
    Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7789-93 PMID: 8356085
  12. Process formation in Sf9 cells induced by the expression of a microtubule-associated protein 2C-like construct.
    Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6223-7 PMID: 8327502
  13. Developmentally regulated expression of specific tau sequences.
    Neuron. 1989 Apr;2(4):1389-97 PMID: 2560640
  14. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein.
    Biochem J. 1994 Aug 1;301 ( Pt 3):871-7 PMID: 7519852
  15. Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases.
    FEBS Lett. 1995 Jan 16;358(1):4-8 PMID: 7821426
  16. Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain.
    FEBS Lett. 1994 Apr 4;342(2):203-8 PMID: 8143878
  17. Implication of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer's disease.
    FEBS Lett. 1992 Aug 17;308(2):218-24 PMID: 1323485
  18. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.
    Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7737-41 PMID: 9636220
  19. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.
    Curr Biol. 1994 Dec 1;4(12):1077-86 PMID: 7704571
  20. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions.
    Neuron. 2001 Apr;30(1):135-47 PMID: 11343650
  21. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells.
    Biochem Biophys Res Commun. 2000 Jul 21;274(1):16-21 PMID: 10903889
  22. Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly.
    J Biol Chem. 2000 Aug 11;275(32):24977-83 PMID: 10818091
  23. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments.
    Neurosci Lett. 1992 Dec 14;148(1-2):202-6 PMID: 1284442
  24. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands.
    Am J Hum Genet. 1999 Feb;64(2):414-21 PMID: 9973279
  25. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia.
    Ann Neurol. 2001 Feb;49(2):165-75 PMID: 11220736
  26. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration.
    Neurology. 1999 Sep 11;53(4):864-8 PMID: 10489057
  27. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells.
    Mol Biol Cell. 2000 Dec;11(12):4093-104 PMID: 11102510
  28. FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10.
    FEBS Lett. 1999 Jan 25;443(2):93-6 PMID: 9989582
  29. Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23) transfected cells.
    Biochim Biophys Acta. 1998 Apr 10;1380(2):177-82 PMID: 9565682
  30. Proline-directed and non-proline-directed phosphorylation of PHF-tau.
    J Biol Chem. 1995 Jan 13;270(2):823-9 PMID: 7822317
  31. Competition for microtubule-binding with dual expression of tau missense and splice isoforms.
    Mol Biol Cell. 2001 Jan;12(1):171-84 PMID: 11160831
  32. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements.
    Proc Natl Acad Sci U S A. 1999 May 11;96(10):5598-603 PMID: 10318930
  33. Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy.
    Neurology. 2002 Feb 26;58(4):589-92 PMID: 11865137
  34. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles.
    Science. 2001 Jul 27;293(5530):711-4 PMID: 11408621
  35. Neurotoxicity induces cleavage of p35 to p25 by calpain.
    Nature. 2000 May 18;405(6784):360-4 PMID: 10830966
  36. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta.
    Mol Cell Neurosci. 1997;9(3):220-34 PMID: 9245504
  37. A brain-specific activator of cyclin-dependent kinase 5.
    Nature. 1994 Sep 29;371(6496):423-6 PMID: 8090222
  38. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5.
    FEBS Lett. 1993 Dec 28;336(3):417-24 PMID: 8282104
  39. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.
    Nature. 1998 Jun 18;393(6686):702-5 PMID: 9641683
  40. Tau protein kinase I/GSK-3 beta/kinase FA in heparin phosphorylates tau on Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 sites phosphorylated in Alzheimer disease brain.
    J Protein Chem. 1995 Feb;14(2):95-105 PMID: 7786411
  41. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau.
    J Neuropathol Exp Neurol. 1999 Jun;58(6):667-77 PMID: 10374757
  42. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants.
    Ann Neurol. 1997 Jun;41(6):706-15 PMID: 9189031
  43. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25.
    J Biol Chem. 2000 Jun 2;275(22):17166-72 PMID: 10748088
  44. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5.
    Nature. 1994 Sep 29;371(6496):419-23 PMID: 8090221
  45. Tau gene mutation in familial progressive subcortical gliosis.
    Nat Med. 1999 Apr;5(4):454-7 PMID: 10202939
  46. Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation.
    Ann Neurol. 2002 Apr;51(4):525-30 PMID: 11921059
  47. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons.
    Nature. 1992 Dec 17;360(6405):674-7 PMID: 1465130
  48. Vac8p, a vacuolar protein with armadillo repeats, functions in both vacuole inheritance and protein targeting from the cytoplasm to vacuole.
    J Cell Biol. 1998 Mar 9;140(5):1063-74 PMID: 9490720
  49. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation.
    Genes Dev. 1996 Apr 1;10 (7):816-25 PMID: 8846918
  50. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress.
    J Cell Biol. 2002 Mar 18;156(6):1051-63 PMID: 11901170
  51. Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract.
    J Biochem. 1995 Apr;117(4):741-9 PMID: 7592534
  52. Tau is a candidate gene for chromosome 17 frontotemporal dementia.
    Ann Neurol. 1998 Jun;43(6):815-25 PMID: 9629852
  53. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau.
    J Cell Biol. 1994 Mar;124(5):769-82 PMID: 8120098
  54. Tau protein kinase II is involved in the regulation of the normal phosphorylation state of tau protein.
    J Neurochem. 1993 Feb;60(2):461-8 PMID: 8419532
  55. Nonsaturable binding indicates clustering of tau on the microtubule surface in a paired helical filament-like conformation.
    J Biol Chem. 2000 Sep 29;275(39):30335-43 PMID: 10869348
Article Info
Journal
Journal of molecular neuroscience : MN
Abbr.
J Mol Neurosci
ISSN
0895-8696
DOI
10.1385/JMN:19:3:261
Email
[email protected]
Published
2002-12-00
Pages
261-6
Language
English
Region
United States
NLM ID
9002991
Subset
IM
External Links
PubMed source DOI: 10.1385/JMN:19:3:261 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2